All In Biotech

Drug Trial Radar · NCT02877927

Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Last checked: Nov 20, 2026Latest source record: Nov 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 735 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

735

Actual

Start

Aug 2016

Primary completion

May 26, 2017

Study completion Jun 6, 2017

Sponsor

Lead sponsor
Paratek Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Aug 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.

Conditions

  • Bacterial Infections
  • Skin Structures and Soft Tissue Infections

Interventions

  • OmadacyclineDrug

    po tablets

  • LinezolidDrug

    po tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Early Clinical ResponseTime frame: Screening; 48 to 72 hours after the first dose of test article

Locations

50 sites in 1 country. Site status is shown where the registry gives one.

  • Site 620

    Birmingham, Alabama

  • Site 642

    Mobile, Alabama

  • Site 616

    Anaheim, California

  • Site 601

    Anaheim, California

  • Site 636

    Bakersfield, California

  • Site 606

    Buena Park, California

  • Site 604

    Chula Vista, California

  • Site 659

    Huntington Beach, California

  • Site 608

    La Mesa, California

  • Site 618

    Laguna Hills, California

  • Site 612

    Long Beach, California

  • Site 648

    Modesto, California

  • Site 610

    Oceanside, California

  • Site 615

    San Diego, California

  • Site 621

    San Diego, California

  • Site 613

    San Francisco, California

  • Site 603

    Stockton, California

  • Site 650

    Torrance, California

  • Site 646

    Ventura, California

  • Site 614

    DeLand, Florida

  • Site 655

    Fort Myers, Florida

  • Site 656

    Homestead, Florida

  • Site 631

    Miami, Florida

  • Site 658

    Miami, Florida

  • Site 654

    Miami, Florida

  • Site 626

    Miami, Florida

  • Site 637

    Miami, Florida

  • Site 653

    Miami, Florida

  • Site 641

    Miami, Florida

  • Site 645

    Miami, Florida

  • Site 640

    Miami Lakes, Florida

  • Site 662

    Miami Lakes, Florida

  • Site 609

    Saint Cloud, Florida

  • Site 644

    Council Bluffs, Iowa

  • Site 657

    Boston, Massachusetts

  • Site 617

    St Louis, Missouri

  • Site 602

    Butte, Montana

  • Site 623

    Las Vegas, Nevada

  • Site 630

    Somers Point, New Jersey

  • Site 647

    Jackson Heights, New York

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.